Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02834299
Other study ID # 3379
Secondary ID
Status Completed
Phase N/A
First received July 6, 2016
Last updated March 28, 2018
Start date September 20, 2016
Est. completion date March 20, 2018

Study information

Verified date March 2018
Source Memorial University of Newfoundland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare unguided and guided dialectical behavior therapy (DBT) self-help to an attention-placebo self-help control condition. Participants with binge eating disorder will be randomly assigned to one of the three self-help conditions for 12 weeks. Six guided self-help sessions will take place via secure video-calling. Assessments will take place before, mid-way through, and after the self-help program as well as at 3-month follow-up. Six guided self-help sessions will take place via secure video-calling.


Description:

STUDY OBJECTIVES AND HYPOTHESES The primary objective of this randomized controlled trial is to compare the effectiveness of two methods of administering a dialectical behavior therapy (DBT) self-help intervention in a community sample of individuals with BED in NL: guided DBT self-help (DBT-GSH) and unguided DBT self-help (DBT-USH). A third condition designed to control for non-specific or common factors (e.g., receiving a self-help book) will also be included (NS-SH). This condition will be a self-help manual focused on improving low self-esteem using CBT strategies with no reference to binge eating.

METHODS

Sample size calculation:

Power analysis was based on the primary outcome variable: frequency of binge eating episodes. Assuming the three randomized groups (DBT-USH, DBT-GSH and NS-UGS) are equivalent at baseline, a between groups ANOVA will be used to compare them at post-treatment. Based on the findings of Masson et al. (2014), assuming an effect size of 0.40 and Type 1 error rate equal to .05, a sample size of at least 21 participants per group will yield 80% power. Assuming an attrition rate of 20%, we will require 25 participants per group.

Procedure:

Recruitment: Participants will be recruited from the community in the province of Newfoundland and Labrador (NL), Canada. Family doctor practices around the province will be informed about the study and brochures/posters will be sent to them. Posters advertising the study will be posted in hospitals, colleges, medical clinics, and universities. Advertisements will be placed on a local radio website and the PI will appear on the radio to advertise the study. Interested participants will be instructed to go to a website where they will fill in an initial screening questionnaire. Those who appear to meet the study inclusion criteria will be scheduled for an initial assessment interview via telephone or video-calling to confirm their eligibility.

Study inclusion/exclusion criteria:

Inclusion criteria: Participants will be male or female aged 18 and older who meet the DSM-5 diagnostic criteria for BED based on Eating Disorder Examination (Version 17). Additional inclusion criteria will include: 1) body mass index (BMI; kg/m2) of at least 18.5; 2) ability to read English; 3) high school graduate or equivalent; and 4) access to a computer, tablet or cell phone (with camera and microphone) and to high speed internet.

Exclusion criteria: Participants will be excluded for the following reasons: a) current specialized psychological treatment specifically for BED; b) current major medical illness that would interfere with treatment (e.g., cancer); c) current acute suicidal risk as assessed using the BDI-II ; d) current substance use disorder; and e) current psychotic symptoms . Individuals on a stable dose of antidepressant medication and/or sleep medication for at least 3 months will be eligible to take part.

Randomization: Participants will be randomized to one of the three intervention conditions (DBT-USH or DBT-GSH or NS-SH) using block randomization, with a block size of 5. Since no reliable predictors of BED outcome have been identified to date, we will not stratify the groups. The randomization list will be prepared by a research assistant not involved in the current study.

Interventions: Treatment will last 12 weeks in all conditions. Participants in both DBT self-help conditions will be provided with the DBT self-help manual "Dialectical Behavior Therapy for Binge Eating: A Self-Help Program". This manual is a self-help version of the well-established therapist-administered DBT treatment manual used in previous trials of DBT for BED. It consists of nine modules that aim to teach three skills to help participants stop binge eating: mindfulness, distress tolerance and emotion regulation. In the GSH condition, participants will receive six 30-minute one-on-one GSH sessions via a secure web-based video-calling program (Bluejeans) with a clinical psychology doctoral student therapist. GSH sessions will take place weekly for the first 2 weeks, biweekly for 6 weeks and then a final session will take place at week 12. The video-calling program allows GSH sessions to be recorded for supervision and treatment monitoring purposes. GSH therapists will have weekly group supervision meetings with the principal investigator to discuss any questions or challenges that arise. In both unguided self-help conditions, participants will be asked to do their best to follow the advice in the self-help manual on their own over the next 12 weeks.

Therapist Training and Supervision: After completing preparatory readings, therapists will attend a half-day training workshop with the principal investigator (JCM). Thereafter, therapists will meet weekly with JCM for group supervision to ensure competence and adherence to the GSH therapist manual.

Guided Self-Help (GSH) Therapist Manual. This manual was used in three previous CBT GSH trials, including one by the PI. It was adapted for the present study to guide therapists' DBT-GSH sessions.

Therapist Adherence to the GSH Therapist Manual: A random sample of 15% of video-taped GSH sessions will be reviewed by an independent rater to insure adherence to the Therapist Manual.

Participant drop-out: Consistent with an intention-to-treat approach, participants who drop out will be asked to continue to participate in the study assessments. To assess participant adherence, we will measure the number of times participants access the self-help manual website and the number of minutes they spend on each module. The number of eligible individuals who: decline to participate, are randomized, begin the study, or drop out of the study (and the week at which this occurs) will be recorded.

Assessment Measures: Except for the initial assessment interview, which will be conducted via video-calling, all study measures will be administered on-line via Qualtrics. Measures will be administered at baseline (Week 1), and post-treatment (Week12), as well as 3-month follow-up. A subset of measures (EDE-Q and DERS) will also be administered at mid-treatment (week 6).

Demographic variables:

Age, body weight, height, weight history, marital status, education level, ethnicity, age of onset of binge eating, and treatment history will be collected at baseline. Body weight will also be re-assessed at mid- and post-treatment.

Eating Disorder Psychopathology:

- Eating Disorder Examination Interview, Version 17 (EDE).

- Eating Disorder Examination Questionnaire (EDE-Q 6.0). General Psychological Distress

- Brief Symptom Inventory (BSI). Emotion Regulation

- Difficulties with Emotion Regulation Scale (DERS). Treatment Suitability and Expectancy (TSE)

- Perceived treatment suitability and expectations will be measured at baseline using two 10-point visual analogue scales used in previous self-help study on eating disorders.

Statistical analyses: The primary analysis will focus on the main outcome variable - number of binge eating episodes over the previous 28 days. If, after randomization, the three groups (i.e., GSH and USH) are equivalent at baseline, then an ANOVA will be used to compare the groups on binge eating frequency at post-treatment. Impact on eating disorder psychopathology, general psychological distress, quality of life, and difficulties with emotion regulation will also be examined. Eating disorder psychopathology, general psychological distress, quality of life, and difficulties with emotion regulation will also be examined.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date March 20, 2018
Est. primary completion date March 20, 2018
Accepts healthy volunteers No
Gender All
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria:

- meets DSM 5 criteria for binge eating disorder (BED)

Exclusion Criteria:

- receiving specialized psychological treatment for BED,

- BMI under 18.5,

- substance use disorder, major medical illness, psychotic symptoms

Study Design


Intervention

Behavioral:
DBT Guided Self-Help
DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
DBT Unguided Self-Help
DBT self-help manual without any therapy sessions for 12 weeks
Self-Esteem-Focused Unguided Self-Help
Self-esteem focused self-help manual without any therapy sessions for 12 weeks

Locations

Country Name City State
Canada Memorial University of Newfoundland St. John's Newfoundland & Labrador

Sponsors (1)

Lead Sponsor Collaborator
Memorial University of Newfoundland

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Eating Disorder Examination Questionnaire measures core eating disorder psychopathology and binge eating Change from baseline at Week 12
Secondary Difficulties in Emotion Regulation Scale Measures deficits in emotion management skills Change from baseline at Week 12
Secondary Brief Symptom Inventory measures general psychological distress Change from baseline at Week 12
See also
  Status Clinical Trial Phase
Withdrawn NCT02978742 - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder N/A
Recruiting NCT02659488 - Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects Phase 2
Completed NCT02659475 - Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED) Phase 2
Completed NCT00601653 - Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder N/A
Completed NCT02553824 - FDA Approved Medication to Reduce Binge Eating and/or Purging Phase 1
Completed NCT02564588 - Dasotraline Binge Eating Disorder Study Phase 2/Phase 3
Completed NCT00307190 - Hormone Release and Stomach Disturbances in People With Binge Eating Disorder N/A
Completed NCT01718483 - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Phase 3
Completed NCT01718509 - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Phase 3
Completed NCT02503098 - Optimizing a Smartphone Application for Individuals With Eating Disorders N/A
Active, not recruiting NCT01837953 - Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial N/A
Completed NCT01010789 - Armodafinil in Binge Eating Disorder (BED) Phase 3
Completed NCT01098435 - ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder Phase 2
Completed NCT01552759 - Appetite Hormones in Binge Eating Disorder N/A
Completed NCT00330655 - An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Phase 4
Completed NCT01291173 - Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder Phase 2
Completed NCT03107026 - A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Phase 3
Completed NCT02079935 - Treatment of Eating Disorders by Physical Activity and Nutrition Counseling N/A
Completed NCT00277641 - Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Phase 3
Completed NCT00032760 - Meditation-Based Treatment for Binge Eating Disorder Phase 2/Phase 3